Behcet's Disease Therapeutics Trends That Will Disrupt the Market
According to a recent Technavio report, the Behcet's disease therapeutics market is expected to grow by USD 224.55 million during 2019-2023. Growth in the Behcet's disease therapeutics market can be attributed to many segments, one of which is the product segment comprising of small molecules and biologics. Industry participants are focusing on analyzing maximum growth opportunities in the market by considering their prospects in the fast-growing product segment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104005698/en/
What are the Latest Trends?
There is a huge unmet need for the treatment of Behcet’s disease associated with genetic mutations and autoimmune disorders. Major Behcet's disease therapeutics market trends, such as the advent of novel therapies will drive the market growth. This is encouraging many academic institutions and pharmaceutical companies to invest substantially in the R&D of novel therapies. Regenerative medicines such as gene therapy and hemopoietic cell transplantations are a few of the most advanced and heavily researched treatment methods. Most of the therapies are either in the discovery stage or pre-clinical stage. As per Technavio, the Behcet's disease therapeutics market is forecast to grow at a CAGR of over 6% by 2023.
Get A Free Sample Analysis from the Behcet’s Disease Therapeutics Market Analysis
Companies are currently conducting research on novel gene therapies, among which, some are in the discovery stage and some in pre-clinical stage. These companies are attracted to start the research on gene therapy for Behcet’s disease due to recent advances in the research methods of these novel therapies.
Register for a free trial today and gain instant access to 10,000+ market research reports.
Developments in the field of Behcet's Disease Therapeutics
Several vendors in the market are focusing on developing new products. For instance, Mylan NV has offered HULIO. It is a biosimilar of HUMIRA and used for the treatment of various autoimmune diseases such as Behcet’s disease.
Eisai Co. Ltd. is one of the several vendors operating in the Behcet's disease therapeutics space. The company offers HUMIRA, which is extensively used by patients suffering from autoimmune diseases such as Behcet’s disease. It helps in alleviating pain and inflammation in these patients.
For Further Market Information
More insights like this on the U.S. and global markets can be found in a series of reports published by Technavio entitled the Osteonecrosis Therapeutics Market Analysis, Size, Trends | Global | 2019-2023 & Splenomegaly Therapeutics Market Analysis, Size, Trends | Global | 2019-2023.
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
Technavio is an international consulting and market research firm dedicated to empowering confident strategic decisions within the medical device, dental, pharmaceutical and more Healthcare industries.